654671-78-0 | (2R)​-​4-​Oxo-​4-​[3-​(trifluoromethyl)​-​5,​6-​dihydro-​[1,​2,​4]​triazolo[4,​3-​a]​pyrazin-​7(8H)​-​yl]​-​1-​(2,​4,​5-​trifluorophenyl)​butan-​2-​amine dihydrogen phosphate

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$8.00	$5.00
250mg	98%	in stock	$10.00	$7.00
1g	98%	in stock	$22.00	$15.00
25g	98%	in stock	$525.00	$368.00

Description

• Catalog Number: AB79004
• Chemical Name: (2R)​-​4-​Oxo-​4-​[3-​(trifluoromethyl)​-​5,​6-​dihydro-​[1,​2,​4]​triazolo[4,​3-​a]​pyrazin-​7(8H)​-​yl]​-​1-​(2,​4,​5-​trifluorophenyl)​butan-​2-​amine dihydrogen phosphate
• CAS Number: 654671-78-0
• Molecular Formula: C16H18F6N5O5P
• Molecular Weight: 505.30880019999995
• MDL Number: MFCD09952339
• SMILES: OP(=O)(O)O.N[C@H](Cc1cc(F)c(cc1F)F)CC(=O)N1CCn2c(C1)nnc2C(F)(F)F

Computed Properties

• Complexity: 616
• Covalently-Bonded Unit Count: 2
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 14
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 4

Literature

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• High fat diet and GLP-1 drugs induce pancreatic injury in mice.

  Toxicology and applied pharmacology 20140415

• Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations.

  Journal of molecular modeling 20140401

• Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats.

  Chemico-biological interactions 20130425

• A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

  European journal of pharmacology 20121205

• Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

  Regulatory peptides 20121110

• Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

  Journal of clinical pharmacology 20121001

• Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20121001

• Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.

  Diabetes, obesity & metabolism 20121001

• No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

  Diabetes, obesity & metabolism 20121001

• Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

  Diabetes research and clinical practice 20121001

• Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

  Diabetes care 20121001

• Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

  Diabetes technology & therapeutics 20121001

• Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

  Diabetes & metabolism 20121001

• Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.

  Journal of cardiac failure 20121001

• Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.

  Advances in therapy 20121001

• Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

  Diabetes, obesity & metabolism 20120901

• Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.

  Diabetes, obesity & metabolism 20120901

• The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

  Journal of diabetes 20120901

• Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease.

  Naunyn-Schmiedeberg's archives of pharmacology 20120901

• Sitagliptin exerts an antinflammatory action.

  The Journal of clinical endocrinology and metabolism 20120901

• Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.

  Hypertension (Dallas, Tex. : 1979) 20120901

• Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.

  Hypertension (Dallas, Tex. : 1979) 20120901

• [Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].

  MMW Fortschritte der Medizin 20120823

• Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

  Clinical endocrinology 20120801

• Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.

  The Journal of dermatology 20120801

• Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

  Diabetes, obesity & metabolism 20120801

• Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

  Diabetes, obesity & metabolism 20120801

• Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

  Diabetologia 20120801

• Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20120801

• Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.

  Current medical research and opinion 20120801

• The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.

  Alimentary pharmacology & therapeutics 20120801

• Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.

  Current medical research and opinion 20120801

• Mechanism of action of DPP-4 inhibitors--new insights.

  The Journal of clinical endocrinology and metabolism 20120801

• Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.

  Diabetes, obesity & metabolism 20120701

• Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.

  Diabetes, obesity & metabolism 20120701

• The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

  Diabetes technology & therapeutics 20120701

• Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.

  Current medical research and opinion 20120701

• Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

  Current medical research and opinion 20120701

• [Liraglutide: new results in the treatment of type 2 diabetes mellitus].

  Drugs of today (Barcelona, Spain : 1998) 20120701

• Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

  Lancet (London, England) 20120616

• Choosing a blood-glucose-lowering agent after metformin.

  Lancet (London, England) 20120616

• Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120615

• [Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].

  Zhonghua yi xue za zhi 20120612

• Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

  Acta diabetologica 20120601

• Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

  Diabetes, obesity & metabolism 20120601

• Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

  Expert opinion on drug metabolism & toxicology 20120601

• Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.

  Acta gastro-enterologica Belgica 20120601

• Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.

  Diabetic medicine : a journal of the British Diabetic Association 20120501

• Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20120501

• Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.

  Diabetes, obesity & metabolism 20120501

• Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.

  European journal of clinical pharmacology 20120501

• An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

  Current diabetes reviews 20120501

• Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.

  International journal of clinical practice 20120501

• Immunotherapies in diabetes mellitus type 1.

  The Medical clinics of North America 20120501

• Association between sitagliptin adherence and self-monitoring of blood glucose.

  Journal of diabetes science and technology 20120501

• Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.

  Chinese medical journal 20120501

• The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.

  American journal of physiology. Gastrointestinal and liver physiology 20120415

• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  Diabetes & metabolism 20120401

• Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.

  Neurobiology of disease 20120401

• The design of the liraglutide clinical trial programme.

  Diabetes, obesity & metabolism 20120401

• Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

  Diabetic medicine : a journal of the British Diabetic Association 20120301

• Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.

  The Journal of the Association of Physicians of India 20120301

• Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.

  Oncogene 20120223

• The importance of green chemistry in process research and development.

  Chemical Society reviews 20120221

• Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).

  Dermatology online journal 20120215

• Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.

  Diabetes research and clinical practice 20120201

• Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.

  Experimental hematology 20120201

• Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.

  Endocrinology 20120201

• Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

  Diabetes care 20120201

• Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.

  The Australasian journal of dermatology 20120201

• A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

  Journal of the American College of Cardiology 20120117

• Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection.

  Journal of the American College of Cardiology 20120117

• Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.

  Journal of nephrology 20120101

• Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.

  European journal of heart failure 20120101

• Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20120101

• The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

  Diabetes research and clinical practice 20120101

• Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.

  Dermatology (Basel, Switzerland) 20120101

• Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Why do metabolites circulate?

  Xenobiotica; the fate of foreign compounds in biological systems 20120101

• Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

  Translational research : the journal of laboratory and clinical medicine 20120101

• Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.

  Hepato-gastroenterology 20120101

• Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan.

  Endocrine journal 20120101

• [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101

• Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.

  Endocrine journal 20120101

• Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.

  Journal of medical economics 20120101

• Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.

  PloS one 20120101

• Reversible mitral and aortic regurgitation due to pioglitazone.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

• Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

  BMC pharmacology 20120101

• Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.

  PloS one 20120101

• Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.

  CANNT journal = Journal ACITN 20120101

• A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy.

  Endocrine research 20120101

• Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

  Journal of medical economics 20120101

• Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.

  Internal medicine (Tokyo, Japan) 20120101

• Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

  Cardiovascular diabetology 20120101

• The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.

  TheScientificWorldJournal 20120101

• Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.

  Pharmacology 20120101

• The effects of simvastatin on the pharmacokinectics of sitagliptin.

  Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 20120101

• Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

  Journal of molecular and cellular cardiology 20111201

• Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.

  Transplantation 20111127

• [Incretin-based therapy for treating patients with type 2 diabetes].

  Orvosi hetilap 20111127

• Sitagliptin and simvastatin (juvisync).

  The Medical letter on drugs and therapeutics 20111114

• Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

  Diabetes, obesity & metabolism 20111101

• Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.

  Diabetes technology & therapeutics 20111101

• Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.

  Diabetes research and clinical practice 20111101

• Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.

  Xenobiotica; the fate of foreign compounds in biological systems 20111101

• The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

  International journal of clinical practice 20111101

• Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.

  Prescrire international 20111101

• Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.

  BMB reports 20111101

• [Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].

  Drugs of today (Barcelona, Spain : 1998) 20111101

• Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

  Diabetic medicine : a journal of the British Diabetic Association 20111001

• Evaluation of the interaction between sitagliptin and cyclodextrin derivatives by capillary electrophoresis and nuclear magnetic resonance spectroscopy.

  Electrophoresis 20111001

• [Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

  Orvosi hetilap 20110911

• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.

  Journal of clinical pharmacology 20110901

• Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.

  Expert opinion on pharmacotherapy 20110901

• A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

  Diabetes, obesity & metabolism 20110901

• The metabolic syndrome influences the response to incretin-based therapies.

  Acta diabetologica 20110901

• Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

  International journal of clinical practice 20110901

• Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110901

• Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

  Journal of medicinal chemistry 20110825

• Development of a molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine.

  Talanta 20110815

• Merging the best of two worlds: artificial metalloenzymes for enantioselective catalysis.

  Chemical communications (Cambridge, England) 20110814

• Inhibition of anaphylaxis like reaction and mast cell activation by Sitagliptin.

  International immunopharmacology 20110801

• DPP-IV inhibitor may affect spermatogenesis.

  Diabetes research and clinical practice 20110801

• Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

  Endocrinology 20110801

• Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.

  Pancreas 20110801

• Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.

  The Journal of biological chemistry 20110722

• Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.

  Talanta 20110715

• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  Gastroenterology 20110701

• The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20110701

• Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.

  Diabetes research and clinical practice 20110701

• Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.

  Diabetes technology & therapeutics 20110701

• Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.

  Pancreas 20110701

• Sitagliptin: a review.

  Expert opinion on pharmacotherapy 20110701

• GLP-1-based therapies: the dilemma of uncertainty.

  Gastroenterology 20110701

• Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

  The Annals of pharmacotherapy 20110701

• Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

  British journal of hospital medicine (London, England : 2005) 20110701

• DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

  Diabetic medicine : a journal of the British Diabetic Association 20110601

• Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20110601

• Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.

  Journal of the American Geriatrics Society 20110601

• Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report.

  Transplantation proceedings 20110601

• [Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry].

  Se pu = Chinese journal of chromatography 20110601

• An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

  Contemporary clinical trials 20110501

• Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

  Diabetes research and clinical practice 20110501

• Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

  Current medical research and opinion 20110501

• [Incretin enhancer: sitagliptin].

  Nihon rinsho. Japanese journal of clinical medicine 20110501

• Journal withdraws article after complaints from drug manufacturers.

  BMJ (Clinical research ed.) 20110411

• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20110401

• One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.

  International journal of clinical practice 20110401

• [Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].

  Wiener klinische Wochenschrift 20110401

• Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

  Journal of hypertension 20110301

• Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.

  Biological chemistry 20110301

• Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.

  Biological chemistry 20110301

• Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

  Diabetes, obesity & metabolism 20110301

• Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

  British journal of clinical pharmacology 20110301

• Sitagliptin and metformin--novel combination therapy.

  Expert opinion on pharmacotherapy 20110301

• Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.

  Diabetic medicine : a journal of the British Diabetic Association 20110301

• Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.

  Experimental biology and medicine (Maywood, N.J.) 20110301

• A diabetes drug, sitagliptin, also has a potential to prevent diabetes.

  Experimental biology and medicine (Maywood, N.J.) 20110301

• Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.

  Angewandte Chemie (International ed. in English) 20110225

• Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

  Drugs 20110212

• Severe leucopenia associated with Sitagliptin use.

  Diabetes research and clinical practice 20110201

• Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.

  American journal of physiology. Endocrinology and metabolism 20110201

• Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.

  Endocrinology 20110201

• Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

  Diabetes, obesity & metabolism 20110201

• Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

  International journal of clinical practice 20110201

• Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

  Diabetes care 20110201

• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.

  The Tohoku journal of experimental medicine 20110201

• Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.

  The Journal of the American Osteopathic Association 20110201

• Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

  Hospital practice (1995) 20110201

• Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

  Journal of medicinal chemistry 20110127

• Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.

  Regulatory peptides 20110117

• Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.

  Clinical science (London, England : 1979) 20110101

• Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

  Diabetes, obesity & metabolism 20110101

• Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.

  Diabetes technology & therapeutics 20110101

• Sitagliptin reduces albuminuria in patients with type 2 diabetes.

  Endocrine journal 20110101

• Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

  Postgraduate medicine 20110101

• A case of drug-induced hepatic injury associated with sitagliptin.

  Internal medicine (Tokyo, Japan) 20110101

• Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

• Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

  Clinical drug investigation 20110101

• [Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study 'SUGAR'].

  Revue medicale de Liege 20110101

• Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus.

  Hepato-gastroenterology 20110101

• Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.

  PloS one 20110101

• A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.

  Cardiovascular diabetology 20110101

• Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

  Experimental diabetes research 20110101

• Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters.

  Xenobiotica; the fate of foreign compounds in biological systems 20101201

• [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].

  Drugs of today (Barcelona, Spain : 1998) 20101201

• Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis.

  International journal of cardiology 20101119

• Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

  Diabetes care 20101101

• DPP-4 inhibitors: what may be the clinical differentiators?

  Diabetes research and clinical practice 20101101

• Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.

  International journal of clinical practice 20101101

• [New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].

  MMW Fortschritte der Medizin 20101007

• Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.

  Hypertension (Dallas, Tex. : 1979) 20101001

• Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

  Hypertension (Dallas, Tex. : 1979) 20101001

• Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

  Expert opinion on drug metabolism & toxicology 20101001

• Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.

  Diabetes research and clinical practice 20101001

• Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

  Diabetes/metabolism research and reviews 20101001

• Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.

  Diabetes, obesity & metabolism 20101001

• Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

  Clinical pharmacokinetics 20100901

• Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Patient education and self-management.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Introduction.

  The Journal of family practice 20100901

• Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.

  The Journal of family practice 20100901

• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  Lancet (London, England) 20100807

• Individualised incretin-based treatment for type 2 diabetes.

  Lancet (London, England) 20100807

• The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.

  Clinical endocrinology 20100801

• Dipeptidyl-peptidase 4 and attractin expression is increased in circulating blood monocytes of obese human subjects.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20100801

• Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

  Diabetes care 20100801

• Managing type 2 diabetes in the primary care setting: beyond glucocentricity.

  The American journal of the medical sciences 20100801

• Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

  Diabetes, obesity & metabolism 20100801

• Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.

  Expert opinion on investigational drugs 20100801

• Sitagliptin in treatment of diabetes complicated by chronic hepatitis C.

  Hepatobiliary & pancreatic diseases international : HBPD INT 20100801

• Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.

  The American journal of managed care 20100801

• Biocatalytic asymmetric synthesis of chiral amines from ketones applied to sitagliptin manufacture.

  Science (New York, N.Y.) 20100716

• Biochemistry. Reengineering enzymes.

  Science (New York, N.Y.) 20100716

• Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.

  Archives of internal medicine 20100712

• The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

  Diabetes care 20100701

• Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

  Diabetes 20100701

• Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.

  Clinical and experimental pharmacology & physiology 20100701

• Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.

  Current medical research and opinion 20100701

• Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.

  Diabetes, obesity & metabolism 20100701

• Determination of sitagliptinin human plasma using protein precipitation and tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100701

• Incretin physiology and its role in type 2 diabetes mellitus.

  The Journal of the American Osteopathic Association 20100701

• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  Health technology assessment (Winchester, England) 20100701

• [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

  Orvosi hetilap 20100620

• Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.

  Clinical science (London, England : 1979) 20100608

• Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.

  Metabolism: clinical and experimental 20100601

• Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

  International journal of clinical practice 20100601

• Diabesity: therapeutic options.

  Diabetes, obesity & metabolism 20100601

• The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA.

  American journal of physiology. Heart and circulatory physiology 20100501

• Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100501

• Choosing among the incretin agents and why it matters.

  The Journal of family practice 20100501

• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  Lancet (London, England) 20100424

• [New hypoglycemic agents in type 2 diabetes].

  La Revue du praticien 20100420

• Costs and consequences associated with newer medications for glycemic control in type 2 diabetes.

  Diabetes care 20100401

• Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

  Diabetes 20100401

• Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20100401

• Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.

  International journal of clinical practice 20100401

• Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.

  Advances in therapy 20100401

• Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report.

  Diabetic medicine : a journal of the British Diabetic Association 20100401

• Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report.

  Diabetic medicine : a journal of the British Diabetic Association 20100401

• Sitagliptin: too many cases of pancreatitis.

  Prescrire international 20100401

• Sitagliptin: a review of its use in the management of type 2 diabetes mellitus.

  Drugs 20100305

• Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.

  Experimental gerontology 20100301

• Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100301

• DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.

  Circulation. Cardiovascular imaging 20100301

• Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity.

  Diabetes research and clinical practice 20100301

• [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

  Pharmazie in unserer Zeit 20100301

• Incretin-based therapies: review of current clinical trial data.

  The American journal of medicine 20100301

• [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

  Medizinische Klinik (Munich, Germany : 1983) 20100301

• New therapeutic options: management strategies to optimize glycemic control.

  The Journal of the American Osteopathic Association 20100301

• The physiologic role of incretin hormones: clinical applications.

  The Journal of the American Osteopathic Association 20100301

• [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes].

  Revue medicale de Liege 20100301

• Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors.

  ChemMedChem 20100201

• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20100201

• Elevated hepatic enzymes potentially associated with sitagliptin.

  The Annals of pharmacotherapy 20100201

• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  Journal of diabetes and its complications 20100101

• Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ T-cell activation.

  Journal of diabetes and its complications 20100101

• Preprandial single oral dose of sitagliptin does not affect circulating ghrelin and gastrin levels in normal subjects.

  Pharmacology 20100101

• [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

  Nederlands tijdschrift voor geneeskunde 20100101

• Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.

  Endocrine journal 20100101

• Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

  Endocrine journal 20100101

• Sitagliptin intolerance.

  Allergologia et immunopathologia 20100101

• A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

  Pharmacology 20100101

• Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).

  Mediators of inflammation 20100101

• Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.

  Clinical drug investigation 20100101

• Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.

  Gastroenterology 20091201

• The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes.

  Gastroenterology 20091201

• Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.

  Cleveland Clinic journal of medicine 20091201

• Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.

  European journal of pharmacology 20091125

• Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

  Diabetes, obesity & metabolism 20091101

• Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour.

  Schizophrenia research 20091101

• Inventing and understanding catalytic, enantioselective reactions.

  Current opinion in drug discovery & development 20091101

• DPP-4 inhibitors in clinical practice.

  Postgraduate medicine 20091101

• [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].

  MMW Fortschritte der Medizin 20091015

• [Combination antidiabetic therapy. Better control of blood glucose values].

  MMW Fortschritte der Medizin 20091015

• Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.

  Current medical research and opinion 20091001

• Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.

  Journal of clinical pharmacology 20091001

• Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon.

  Journal of managed care pharmacy : JMCP 20091001

• Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.

  Journal of managed care pharmacy : JMCP 20090901

• Defining the importance of daily glycemic control and implications for type 2 diabetes management.

  Postgraduate medicine 20090901

• Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090801

• Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors.

  Bioorganic & medicinal chemistry letters 20090801

• A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.

  Journal of clinical pharmacology 20090801

• Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  Best practice & research. Clinical endocrinology & metabolism 20090801

• Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin.

  Diabetes 20090701

• Highly efficient asymmetric synthesis of sitagliptin.

  Journal of the American Chemical Society 20090701

• Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues.

  The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 20090601

• CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.

  Prescrire international 20090601

• Sitagliptin: serious allergies. Risks greater than benefits.

  Prescrire international 20090601

• Initial therapy for type 2 diabetes. Examination of a combination approach.

  Advance for nurse practitioners 20090601

• [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].

  MMW Fortschritte der Medizin 20090507

• Impact of sitagliptin on markers of beta-cell function: a meta-analysis.

  The American journal of the medical sciences 20090501

• [The value of incretin based therapies].

  Deutsche medizinische Wochenschrift (1946) 20090501

• By the way, doctor. I've had type 2 diabetes for 12 years; I'm now 81. I take metformin plus Januvia. My doctor has never suggested that I monitor myself on a daily basis with a meter. My hemoglobin A1c has been creeping up and is now at 7. Should I be getting more aggressive in my treatment?

  Harvard health letter 20090501

• [Incretin related agents for treatment of diabetes mellitus].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410

• Effect of sitagliptin on the pharmacokinetics of simvastatin.

  Journal of clinical pharmacology 20090401

• Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.

  Current medical research and opinion 20090401

• Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

  Diabetes 20090301

• Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

  Current medical research and opinion 20090301

• Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction.

  Pharmacotherapy 20090301

• Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20090301

• DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy.

  Advances in therapy 20090301

• Dipeptidyl-peptidase-4 inhibitors for treatment of type 2 diabetes.

  American family physician 20090301

• Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy.

  Advances in therapy 20090201

• Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

  Diabetic medicine : a journal of the British Diabetic Association 20090201

• Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?

  Diabetic medicine : a journal of the British Diabetic Association 20090201

• Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.

  Leukemia research 20090101

• Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice.

  Endocrinology 20090101

• Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

  Diabetes research and clinical practice 20090101

• Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.

  Current drug targets 20090101

• Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

  Mymensingh medical journal : MMJ 20090101

• The therapeutic role of incretin mimetics and DPP-4 inhibitors.

  The Diabetes educator 20090101

• Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

  The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20090101

• I read about a new drug for diabetes called Januvia. Should I be interested in it?

  Heart advisor 20090101

• Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme.

  Current medicinal chemistry 20090101

• Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretion.

  Journal of diabetes science and technology 20090101

• DPP4 inhibitors for diabetes--what next?

  Biochemical pharmacology 20081215

• Synthesis and biological evaluation of homopiperazine derivatives with beta-aminoacyl group as dipeptidyl peptidase IV inhibitors.

  Bioorganic & medicinal chemistry letters 20081215

• Incretin-based therapies in type 2 diabetes: a review of clinical results.

  Diabetes research and clinical practice 20081215

• Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

  Diabetes, obesity & metabolism 20081201

• The role of incretins in glucose homeostasis and diabetes treatment.

  Pharmacological reviews 20081201

• Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes.

  Acta bio-medica : Atenei Parmensis 20081201

• Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.

  Vascular health and risk management 20081201

• Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.

  Cardiology clinics 20081101

• [Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1].

  MMW Fortschritte der Medizin 20081030

• Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.

  Current medical research and opinion 20081001

• Janumet: a combination product suitable for use in patients with Type 2 diabetes.

  Expert opinion on investigational drugs 20081001

• [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].

  Deutsche medizinische Wochenschrift (1946) 20081001

• [Sitagliptin].

  Revue de l'infirmiere 20081001

• Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use.

  Diabetic medicine : a journal of the British Diabetic Association 20081001

• Natural products as inspiration for the development of asymmetric catalysis.

  Nature 20080918

• Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20080901

• Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

  Arquivos brasileiros de endocrinologia e metabologia 20080801

• New combination treatments in the management of diabetes: focus on sitagliptin-metformin.

  Vascular health and risk management 20080801

• Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

  Vascular health and risk management 20080801

• [New drugs; exenatide and sitagliptin].

  Nederlands tijdschrift voor geneeskunde 20080726

• Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.

  British journal of clinical pharmacology 20080701

• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

  Diabetes, obesity & metabolism 20080701

• Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

  Current opinion in clinical nutrition and metabolic care 20080701

• Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes.

  Expert opinion on pharmacotherapy 20080701

• Drugs for type 2 diabetes.

  Treatment guidelines from the Medical Letter 20080701

• From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.

  Current opinion in drug discovery & development 20080701

• Three new drugs for type 2 diabetes.

  Drug and therapeutics bulletin 20080701

• DPP4 inhibitors: a new approach in diabetes treatment.

  Advances in therapy 20080701

• Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.

  Diabetes, obesity & metabolism 20080601

• Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.

  Hypertension (Dallas, Tex. : 1979) 20080601

• Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

  Expert opinion on investigational drugs 20080601

• New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

  Expert opinion on pharmacotherapy 20080601

• Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes.

  The AAPS journal 20080601

• Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.

  Diabetes 20080501

• Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.

  Journal of clinical pharmacology 20080501

• Managed care perspective on three new agents for type 2 diabetes.

  Journal of managed care pharmacy : JMCP 20080501

• Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.

  Frontiers in bioscience : a journal and virtual library 20080501

• Treating Hispanic patients for type 2 diabetes mellitus: special considerations.

  The Journal of the American Osteopathic Association 20080501

• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  The Cochrane database of systematic reviews 20080416

• [New drugs; exenatide and sitagliptin].

  Nederlands tijdschrift voor geneeskunde 20080412

• New drug update: 2007.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20080401

• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20080401

• Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.

  Vascular health and risk management 20080401

• [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].

  Lakartidningen 20080401

• What's new in clinical pharmacology and therapeutics.

  WMJ : official publication of the State Medical Society of Wisconsin 20080401

• Sitagliptin: a novel agent for the management of type 2 diabetes mellitus.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080315

• [Sitagliptine (Januvia)].

  Journal de pharmacie de Belgique 20080301

• Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry.

  Journal of pharmaceutical and biomedical analysis 20080213

• Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

  Diabetes research and clinical practice 20080201

• Sensitive liquid chromatography tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction.

  Biomedical chromatography : BMC 20080201

• Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials.

  Current medical research and opinion 20080201

• Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.

  Current medical research and opinion 20080201

• [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

  Revue medicale de Liege 20080201

• [Treatment with new preparations against type 2 diabetes not sufficiently documented].

  Lakartidningen 20080201

• How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment.

  Bone marrow transplantation 20080101

• Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.

  The Diabetes educator 20080101

• DPP-4 inhibitors. A new class of drugs for type 2 diabetes.

  Diabetes self-management 20080101

• What can we learn from drug marketing efficiency?

  BMJ (Clinical research ed.) 20080101

• New therapeutic approaches in type 2 diabetes.

  Acta clinica Belgica 20080101

• Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors.

  Bioorganic & medicinal chemistry letters 20071215

• Unlocking the potential of asymmetric hydrogenation at Merck.

  Accounts of chemical research 20071201

• DPP-4 inhibitors.

  Best practice & research. Clinical endocrinology & metabolism 20071201

• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  Clinical therapeutics 20071201

• New treatments for type 2 diabetes--the DPP4 inhibitors.

  Primary care diabetes 20071201

• Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).

  Drugs of today (Barcelona, Spain : 1998) 20071101

• Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20071001

• [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].

  Vnitrni lekarstvi 20071001

• GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

  Current diabetes reports 20071001

• Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

  Biopharmaceutics & drug disposition 20070901

• Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.

  Biopharmaceutics & drug disposition 20070901

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

  Diabetes, obesity & metabolism 20070901

• Using prandial insulin to achieve glycemic control in type 2 diabetes.

  The Journal of family practice 20070901

• Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

  Diabetes care 20070801

• Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.

  Pharmacotherapy 20070801

• Type 2 diabetes drug boom: is newer better?

  The Johns Hopkins medical letter health after 50 20070801

• Type 2 diabetes: the end of clinical inertia.

  Southern medical journal 20070801

• [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].

  Medizinische Monatsschrift fur Pharmazeuten 20070801

• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  JAMA 20070711

• Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.

  Diabetes care 20070701

• [New concepts in the treatment of type 2 diabetes].

  Der Internist 20070701

• New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.

  Heart advisor 20070701

• Management of comorbid diabetes and cancer.

  Oncology (Williston Park, N.Y.) 20070701

• Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.

  Bioorganic & medicinal chemistry letters 20070615

• Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).

  Bioorganic & medicinal chemistry letters 20070615

• Sitagliptin/metformin (Janumet) for type 2 diabetes.

  The Medical letter on drugs and therapeutics 20070604

• Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.

  Diabetes care 20070601

• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

  Current medical research and opinion 20070601

• Janumet.

  JAAPA : official journal of the American Academy of Physician Assistants 20070601

• New treatments for diabetes.

  The New England journal of medicine 20070524

• New treatments for diabetes.

  The New England journal of medicine 20070524

• New treatments for diabetes.

  The New England journal of medicine 20070524

• New treatments for diabetes.

  The New England journal of medicine 20070524

• Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20070501

• Synthesis, biological evaluation and structural determination of beta-aminoacyl-containing cyclic hydrazine derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors.

  Bioorganic & medicinal chemistry letters 20070501

• Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.

  Clinical pharmacology and therapeutics 20070501

• Treatment of type 2 diabetes mellitus and the incretin system.

  South Dakota medicine : the journal of the South Dakota State Medical Association 20070501

• Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• Characterization of two cyclic metabolites of sitagliptin.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.

  Drug metabolism and disposition: the biological fate of chemicals 20070401

• Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.

  Expert opinion on investigational drugs 20070401

• [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].

  Orvosi hetilap 20070401

• Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

  Current medical research and opinion 20070401

• [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].

  Revue medicale de Liege 20070401

• Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.

  Vascular health and risk management 20070401

• Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

  Diabetes, obesity & metabolism 20070301

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

  Diabetes, obesity & metabolism 20070301

• Diabetes drug update: how 4 new options stack up.

  The Journal of family practice 20070301

• Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.

  Journal of clinical pharmacology 20070201

• Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.

  Journal of clinical pharmacology 20070201

• Finding new treatments for diabetes--how many, how fast... how good?

  The New England journal of medicine 20070201

• Sitagliptin.

  Nature reviews. Drug discovery 20070201

• (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  Bioorganic & medicinal chemistry letters 20070101

• Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

  International journal of clinical practice 20070101

• Sitagliptin (Januvia) for type 2 diabetes.

  The Medical letter on drugs and therapeutics 20070101

• Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20070101

• New drugs: sitagliptin phosphate, telbivudine, and panitumumab.

  Journal of the American Pharmacists Association : JAPhA 20070101

• New treatment for diabetes.

  FDA consumer 20070101

• Sitagliptin.

  Drugs 20070101

• Sitagliptin: a viewpoint by Mark S. Kipnes.

  Drugs 20070101

• Sitagliptin: a viewpoint by Itamar Raz.

  Drugs 20070101

• Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  Current topics in medicinal chemistry 20070101

• [New class of oral antidiabetic drugs. Effective in combination with metformin].

  MMW Fortschritte der Medizin 20070101

• Sitagliptin: a novel drug for the treatment of type 2 diabetes.

  Cardiology in review 20070101

• First-in-class diabetes drug approved.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20061201

• Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

  Diabetes care 20061201

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

  Diabetes care 20061201

• Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

  Diabetes & vascular disease research 20061201

• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  Lancet (London, England) 20061111

• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  The Journal of clinical endocrinology and metabolism 20061101

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

  Diabetologia 20061101

• DPP-4 inhibitors and their potential role in the management of type 2 diabetes.

  International journal of clinical practice 20061101

• Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

  Current medical research and opinion 20061001

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  Clinical therapeutics 20061001

• Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs.

  Experimental biology and medicine (Maywood, N.J.) 20060901

• Oral agents for type 2 diabetes reduce HbA1c, are weight neutral.

  Geriatrics 20060901

• Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.

  Journal of clinical pharmacology 20060801

• American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA.

  IDrugs : the investigational drugs journal 20060801

• [DPP-4 inhibition raises incretin levels].

  Medizinische Monatsschrift fur Pharmazeuten 20060801

• Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

  Diabetes 20060601

• [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].

  Medizinische Monatsschrift fur Pharmazeuten 20060301

• Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.

  Clinical therapeutics 20060101

• Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20060101

• Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  The Annals of pharmacotherapy 20060101

• The development of a stable, coated pellet formulation of a water-sensitive drug, a case study: development of a stable core formulation.

  Pharmaceutical development and technology 20060101

• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.

  Clinical pharmacology and therapeutics 20051201

• American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.

  IDrugs : the investigational drugs journal 20050801

• MK-431 (Merck).

  Current opinion in investigational drugs (London, England : 2000) 20050401

• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20050113